JP2018518498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518498A5 JP2018518498A5 JP2017566151A JP2017566151A JP2018518498A5 JP 2018518498 A5 JP2018518498 A5 JP 2018518498A5 JP 2017566151 A JP2017566151 A JP 2017566151A JP 2017566151 A JP2017566151 A JP 2017566151A JP 2018518498 A5 JP2018518498 A5 JP 2018518498A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery device
- transdermal delivery
- ketamine
- plasma concentration
- immediate release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037317 transdermal delivery Effects 0.000 claims 21
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 13
- 229960003299 ketamine Drugs 0.000 claims 13
- 230000036470 plasma concentration Effects 0.000 claims 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical group COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 claims 1
- 229940006275 denatonium Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940100640 transdermal system Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185573P | 2015-06-27 | 2015-06-27 | |
| US62/185,573 | 2015-06-27 | ||
| PCT/US2016/039601 WO2017003935A1 (en) | 2015-06-27 | 2016-06-27 | Ketamine transdermal delivery system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518498A JP2018518498A (ja) | 2018-07-12 |
| JP2018518498A5 true JP2018518498A5 (enExample) | 2019-08-08 |
| JP6845162B2 JP6845162B2 (ja) | 2021-03-17 |
Family
ID=57609546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566151A Active JP6845162B2 (ja) | 2015-06-27 | 2016-06-27 | ケタミン経皮送達システム |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11191734B2 (enExample) |
| EP (1) | EP3297620A4 (enExample) |
| JP (1) | JP6845162B2 (enExample) |
| KR (1) | KR102299359B1 (enExample) |
| CN (1) | CN107847469A (enExample) |
| AU (1) | AU2016288188B2 (enExample) |
| CA (1) | CA2987909C (enExample) |
| HK (1) | HK1248578A1 (enExample) |
| WO (1) | WO2017003935A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| EP3193853A1 (en) | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| US11007144B2 (en) | 2016-11-15 | 2021-05-18 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| CA3059598A1 (en) * | 2017-04-20 | 2018-10-25 | Guangzhou Dazhou Biomedicine Ltd. | Transdermal drug delivery system for ketamine |
| CN108785286A (zh) * | 2017-04-28 | 2018-11-13 | 日东电工株式会社 | 透皮吸收制剂 |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| CN107823195A (zh) * | 2017-11-24 | 2018-03-23 | 无锡市精神卫生中心 | R‑氯胺酮在抑郁症急性期治疗中的应用 |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| US12144899B2 (en) * | 2018-04-25 | 2024-11-19 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US20210308040A1 (en) * | 2018-10-26 | 2021-10-07 | Guangzhou Dazhou Biomedicine Ltd. | Ketamine oral transmucosal delivery system |
| CN111346073B (zh) * | 2018-12-21 | 2022-06-10 | 宜昌人福药业有限责任公司 | 一种透皮给药的药物组合物及其制备方法和应用 |
| EP3934632A4 (en) | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| US11752114B2 (en) | 2019-04-17 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system |
| EP3725306A1 (en) | 2019-04-17 | 2020-10-21 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system |
| CA3135552C (en) * | 2019-04-17 | 2023-09-26 | Lts Lohmann Therapie-Systeme Ag | Ketamine containing transdermal therapeutic system comprising free hydroxyl groups |
| CN109966272A (zh) * | 2019-04-30 | 2019-07-05 | 深圳市泛谷药业股份有限公司 | 一种氯胺酮透皮贴剂及其制备方法 |
| GB201912505D0 (en) * | 2019-08-30 | 2019-10-16 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| IL294089B1 (en) | 2019-12-20 | 2026-07-01 | Alar Pharmaceuticals Inc | Injectable, long-acting formulations of ketamine pamoate salts |
| US11559497B2 (en) | 2020-06-19 | 2023-01-24 | Guangzhou Dazhou Biomedicine Ltd. | Transdermal drug delivery system for ketamine |
| EP3949956A1 (en) * | 2020-08-06 | 2022-02-09 | LTS Lohmann Therapie-Systeme AG | Esketamine-suspension-tts |
| WO2024067731A1 (zh) * | 2022-09-30 | 2024-04-04 | 宜昌人福药业有限责任公司 | S-氯胺酮经皮组合物及其制备方法和应用 |
| CN117797131A (zh) * | 2022-09-30 | 2024-04-02 | 宜昌人福药业有限责任公司 | S-氯胺酮经皮组合物及其制备方法和应用 |
| US12005035B1 (en) * | 2023-08-14 | 2024-06-11 | Daniel C. Javitt | Compositions and methods for treatment of chronic pain and depression |
| WO2025037252A1 (en) * | 2023-08-14 | 2025-02-20 | Javitt Daniel C | Compositions and methods for treatment of chronic pain and depression |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635204A (en) * | 1994-03-04 | 1997-06-03 | Montefiore Medical Center | Method for transdermal induction of anesthesia, analgesia or sedation |
| WO1997007750A1 (en) * | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration of ketamine to manage pain and to reduce drug dependency |
| US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| DE60143671D1 (de) | 2001-06-07 | 2011-01-27 | Sang Christine | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists |
| US20030082225A1 (en) | 2001-10-19 | 2003-05-01 | Mason Paul Arthur | Sterile, breathable patch for treating wound pain |
| US6855735B2 (en) | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| US20050148673A1 (en) | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
| EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| JP2006510618A (ja) | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス，インコーポレーテッド | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
| US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| US20050222270A1 (en) | 2004-02-26 | 2005-10-06 | Olney John W | Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis |
| US8741332B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
| EP2932971A1 (en) | 2005-03-04 | 2015-10-21 | Otonomy, Inc. | Ketamine formulations |
| JP2009530385A (ja) * | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| EP2139848A1 (en) | 2007-04-26 | 2010-01-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
| EP2155175B1 (en) * | 2007-06-08 | 2014-03-12 | Samyang Biopharmaceuticals Corporation | Matrix-type transdermal drug delivery system and preparation method thereof |
| CA2729346A1 (en) * | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| AU2009296457A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| US8394759B2 (en) * | 2008-11-21 | 2013-03-12 | Cymbiotics, Inc. | Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes |
| JP2010229045A (ja) * | 2009-03-26 | 2010-10-14 | Mikasa Seiyaku Co Ltd | 経皮吸収型製剤 |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| KR101292768B1 (ko) * | 2010-04-23 | 2013-08-05 | 아이큐어 주식회사 | 경피 흡수 제제 |
| AU2011267474B2 (en) | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| WO2013003669A2 (en) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| US9724315B2 (en) * | 2011-09-30 | 2017-08-08 | Cmpd Licensing, Llc | Compounded transdermal pain management |
| JP6296985B2 (ja) | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| WO2013088135A1 (en) * | 2011-12-14 | 2013-06-20 | Astrazeneca Ab | Gabr-a2 diagnostic |
| ES2663412T3 (es) * | 2012-01-31 | 2018-04-12 | Grünenthal GmbH | Parche farmacéutico para la administración transdérmica de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4-b]indol]-4-amina |
| US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015512418A (ja) | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| MX2015002378A (es) | 2012-08-23 | 2015-09-25 | Stuart L Weg | Composicion ansiolitica, formulacion y metodo de uso. |
| FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
| AU2013328280B2 (en) | 2012-10-08 | 2017-12-21 | Auckland Uniservices Limited | Ketamine derivatives |
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| CA2940057C (en) * | 2014-02-20 | 2017-05-30 | Cura Health Inc. | Transdermal composition for treating pain |
| US11207316B2 (en) | 2014-05-30 | 2021-12-28 | West Virginia University | Ketamine or dextromethorphan formulations and methods of use |
| US10098854B2 (en) | 2014-08-13 | 2018-10-16 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| KR102604397B1 (ko) | 2014-11-04 | 2023-11-21 | 아카디아 파마슈티칼스 인코포레이티드 | 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법 |
| WO2016109427A1 (en) | 2014-12-31 | 2016-07-07 | Icahn School Of Medicine At Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
| WO2016172672A1 (en) | 2015-04-24 | 2016-10-27 | Icahn School Of Medicine At Mount Sinai | Method for treating suicidal ideation |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| WO2017139382A1 (en) | 2016-02-08 | 2017-08-17 | The Texas A&M University System | Combination of adjuvant drugs esketamine and brimonidine for medical treatments |
| WO2017139768A1 (en) | 2016-02-12 | 2017-08-17 | Synergistic Therapeutics, Llc | Sublingual antidepressant lozenge |
| US20170266319A1 (en) | 2016-03-21 | 2017-09-21 | Children's Hospital Medical Center | Methods and compositions for treating conditions associated with spinal cord injury |
| AU2017238859B2 (en) | 2016-03-25 | 2021-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine |
| US20190083420A1 (en) | 2016-03-25 | 2019-03-21 | The Uinited States of America, as represented by the Secretary, Department of Health and Human Serv | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders |
| GB2564990A (en) | 2016-04-01 | 2019-01-30 | Good Pharmaceutical Dev Company Llc | Topical compositions for neuropathic pain |
| AU2017250086A1 (en) | 2016-04-11 | 2018-09-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| US20170348252A1 (en) | 2016-04-21 | 2017-12-07 | Robert Kent | Preparation and Use of Ketamine Derivatives and Ketamine Modifiers in the Treatment of Pain |
| WO2017205666A1 (en) | 2016-05-25 | 2017-11-30 | National Health Research Institutes | Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine |
| US20190380978A1 (en) | 2016-06-03 | 2019-12-19 | Small Pharma Ltd | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof |
| CA3059598A1 (en) | 2017-04-20 | 2018-10-25 | Guangzhou Dazhou Biomedicine Ltd. | Transdermal drug delivery system for ketamine |
-
2016
- 2016-06-27 CN CN201680037543.8A patent/CN107847469A/zh active Pending
- 2016-06-27 WO PCT/US2016/039601 patent/WO2017003935A1/en not_active Ceased
- 2016-06-27 CA CA2987909A patent/CA2987909C/en active Active
- 2016-06-27 AU AU2016288188A patent/AU2016288188B2/en not_active Ceased
- 2016-06-27 KR KR1020187002315A patent/KR102299359B1/ko not_active Expired - Fee Related
- 2016-06-27 JP JP2017566151A patent/JP6845162B2/ja active Active
- 2016-06-27 HK HK18108421.2A patent/HK1248578A1/zh unknown
- 2016-06-27 EP EP16818548.6A patent/EP3297620A4/en not_active Withdrawn
- 2016-06-27 US US15/736,182 patent/US11191734B2/en active Active
-
2021
- 2021-12-02 US US17/540,695 patent/US20220193000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| EA201500553A1 (ru) | Многодневный пластырь для чрескожного введения ротиготина | |
| NZ777261A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| JP2023523155A5 (enExample) | ||
| JP2015528471A5 (enExample) | ||
| TN2015000493A1 (en) | Transdermal delivery system | |
| NZ707640A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| EA201591124A1 (ru) | Трансдермальная система доставки | |
| JP2022087276A (ja) | メマンチン経皮送達システム | |
| JP2016504368A5 (enExample) | ||
| AU2013299885A1 (en) | Pramipexole transdermal delivery for severe headaches | |
| JP2013541583A5 (enExample) | ||
| JP2019502716A5 (enExample) | ||
| PH12014502802B1 (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| BR112022012111A2 (pt) | Sistema terapêutico transdérmico contendo agomelatina | |
| US20090238860A1 (en) | Adhesive Patch Less Irritative to Skin | |
| JP2013527197A5 (enExample) | ||
| RU2010153722A (ru) | Способ повышения эффективности лечения гипофункции яичников у коров | |
| AR108939A1 (es) | Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este | |
| ATE453392T1 (de) | Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungen | |
| TW201927297A (zh) | 卡巴拉汀游離鹼透皮貼劑有效成分之製造方法及卡巴拉汀游離鹼透皮貼劑 | |
| JP2008200450A (ja) | 使いすてカイロつき経皮鎮痛消炎外用絆創膏。 | |
| AR082287A1 (es) | Una formulacion anestesica local formadora de solido | |
| TH101950B (th) | สูตรผสมทางยาสำหรับให้ทางผิวหนัง | |
| TH154739A (th) | ระบบบำบัดผ่านผิวหนังด้วยฟิล์มปกป้องซึ่งยับยั้งการตกผลึก(แผ่นรองกันเปื้อน) |